Top ▲
target has curated data in GtoImmuPdb
Target id: 3019
Nomenclature: indoleamine 2,3-dioxygenase 2
Abbreviated Name: IDO2
Family: 1.13.11.- Dioxygenases
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 420 | 8p11.21 | IDO2 | indoleamine 2,3-dioxygenase 2 | |
Mouse | - | 405 | 8 A2 | Ido2 | indoleamine 2,3-dioxygenase 2 | |
Rat | - | 403 | 16q12.5 | Ido2 | indoleamine 2,3-dioxygenase 2 |
Previous and Unofficial Names |
indoleamine 2 | INDOL1 | indoleamine-pyrrole 2,3 dioxygenase-like 1 |
Database Links | |
Alphafold | Q6ZQW0 (Hs), Q8R0V5 (Mm) |
BRENDA | 1.13.11.52 |
ChEMBL Target | CHEMBL3627587 (Hs), CHEMBL2189159 (Mm) |
Ensembl Gene | ENSG00000188676 (Hs), ENSMUSG00000031549 (Mm), ENSRNOG00000025365 (Rn) |
Entrez Gene | 169355 (Hs), 209176 (Mm), 681319 (Rn) |
Human Protein Atlas | ENSG00000188676 (Hs) |
KEGG Enzyme | 1.13.11.52 |
KEGG Gene | hsa:169355 (Hs), mmu:209176 (Mm), rno:681319 (Rn) |
OMIM | 612129 (Hs) |
Pharos | Q6ZQW0 (Hs) |
RefSeq Nucleotide | NM_194294 (Hs), NM_145949 (Mm) |
RefSeq Protein | NP_919270 (Hs), NP_666061 (Mm) |
UniProtKB | Q6ZQW0 (Hs), Q8R0V5 (Mm) |
Wikipedia | IDO2 (Hs) |
Enzyme Reaction | ||||||||||
|
Download all structure-activity data for this target as a CSV file
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Immunopharmacology Comments |
IDO2 is an enzyme in the tryptophan-kynurenine pathway. It is expressed in immune cells (e.g. dendritic cells and monocytes) which suggests that it plays some role in immune function, but its precise function remains to be fully elucidated. Mice lacking Ido2 produce greater amounts of interleukin-6 (IL-6) and have elevated levels of activated (phosphorylated) Stat3 compared to wild type mice in response to LPS exposure [3]. Overexpression of Ido2 (in mouse macrophages) has the opposite effect, i.e. suppression of IL-6 production and Stat3 activation. These results suggest that pharmacological modulation of Ido2 could be exploited to regulate IL-6/Stat3 signalling as a mechanism to treat immune disorders. |
Physiological Consequences of Altering Gene Expression | ||||||||||
|
1. Banerjee M, Middya S, Shrivastava R, Raina S, Surya A, Yadav DB, Yadav VK, Kapoor KK, Venkatesan A, Smith RA et al.. (2014) Inhibitors of the kynurenine pathway. Patent number: WO2014186035A1. Assignee: Curadev Pharma Private Ltd.. Priority date: 12/03/2014. Publication date: 20/11/2014.
2. Li J, Li Y, Yang D, Hu N, Guo Z, Kuang C, Yang Q. (2016) Establishment of a human indoleamine 2, 3-dioxygenase 2 (hIDO2) bioassay system and discovery of tryptanthrin derivatives as potent hIDO2 inhibitors. Eur J Med Chem, 123: 171-179. [PMID:27475108]
3. Yamamoto Y, Yamasuge W, Imai S, Kunisawa K, Hoshi M, Fujigaki H, Mouri A, Nabeshima T, Saito K. (2018) Lipopolysaccharide shock reveals the immune function of indoleamine 2,3-dioxygenase 2 through the regulation of IL-6/stat3 signalling. Sci Rep, 8 (1): 15917. [PMID:30374077]
1.13.11.- Dioxygenases: indoleamine 2,3-dioxygenase 2. Last modified on 09/05/2023. Accessed on 06/12/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=3019.